Importantly, we confirmed the therapeutic efficacyof GHN105 in a preclinical acute colitis model, and demonstratedbiochemically that orally administered GHN105 could reachand covalently engage STING in vivo in the colon. The gene discussed is STING1; the disease is colitis.